Constipation pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Constipation}} | {{Constipation}} | ||
{{CMG}}; {{AE}} {{M.P}} | |||
==Overview== | ==Overview== | ||
The underlying pathophysiology of constipation involves several processes such as hardening of the stool, paralysis or slow transit, constriction in the lower gastrointestinal system or psychomotor factors. | The underlying pathophysiology of constipation involves several processes such as hardening of the stool, paralysis or slow transit, constriction in the lower gastrointestinal system or psychomotor factors. | ||
==Pathophysiology== | ==Pathophysiology== | ||
Revision as of 13:44, 13 February 2014
|
Constipation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Constipation On the Web |
|
American Roentgen Ray Society Images of Constipation |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]
Overview
The underlying pathophysiology of constipation involves several processes such as hardening of the stool, paralysis or slow transit, constriction in the lower gastrointestinal system or psychomotor factors.
Pathophysiology
- Hardening of the feces: Improper mastication, low dietary fiber, dehydration and medications (aluminium, calcium, diuretic, iron).
- Paralysis or slowed transit: Hypothyroidism, hypokalemia, injured anal sphincter, medications (loperamide, codeine, morphine, tricyclic antidepressants) and severe systemic illness due to other causes.
- Constriction, where part of the intestine or rectum is narrowed or blocked: Diverticulosis, pelvic masses and stenosis.
- Psychosomatic constipation: Functional constipation and irritable bowel syndrome.[1]
References
- ↑ Caldarella MP, Milano A, Laterza F; et al. (2005). "Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion". Am. J. Gastroenterol. 100 (2): 383–9. doi:10.1111/j.1572-0241.2005.40100.x. PMID 15667496.